Molecular Partners AG Sponsored ADR (MOLN)
(Delayed Data from NSDQ)
$3.94 USD
+0.29 (7.95%)
Updated Aug 5, 2025 01:54 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MOLN 3.94 +0.29(7.95%)
Will MOLN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MOLN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MOLN
Here's Why Molecular Partners AG Sponsored ADR (MOLN) Could be Great Choice for a Bottom Fisher
Wall Street Analysts Think Molecular Partners AG Sponsored ADR (MOLN) Could Surge 80.72%: Read This Before Placing a Bet
MOLN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for MOLN
12 Health Care Stocks Moving In Friday's After-Market Session
UBS AM Acquires Significant Stake in Molecular Partners AG
12 Health Care Stocks Moving In Tuesday's After-Market Session
Molecular Partners’ Promising Oncology Developments and Strategic Focus Earn Buy Rating
Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin ...